ACTRN12619001446156
Completed
未知
A prospective, randomised, interventional, crossover, pilot study to assess whether bag mask ventilation in the presence of a Switching Interface is acceptable to anaesthetists.
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Fisher & Paykel Healthcare
- Enrollment
- 49
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Provide written informed consent.
- •2\) Having elective surgery under general anaesthesia with intravenous induction in an
- •operating room with a participating anaesthetist..
- •3\) BMI must be less than 35 kgm\-2\.
Exclusion Criteria
- •1\) Patients in whom CPAP is contraindicated (e.g. pneumothorax, bullous lung disease, craniofacial trauma, airway, foreign body, unstable haemodynamics)
- •2\) Pre\-existing nasal obstruction.
- •3\) Pre\-existing hypoxaemia (Oxygen Saturation less than or equal to 89%).
- •4\) Known cyanotic congenital heart disease.
- •5\) Patients undergoing induction with volatile anaesthetics.
- •6\) Patients undergoing caesarean section.
- •7\) Bleeding in the nose or oropharynx.
- •8\) Patients requiring preoperative oxygen therapy secondary to chronic lung disease.
- •9\) Uncontrolled cardiac arrhythmias.
- •10\) Uncontrolled heart failure.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study to compare the effect of Trehalose over sodium hyaluronate in patients of dry eye diseaseCTRI/2020/04/024605Dr Arvind Kumar Morya384
Completed
Not Applicable
The future of corneal refractive reshaping: can we control myopia or is the risk of corneal compromise too great?Progressing mild childhood myopiaEye - Diseases / disorders of the eyeACTRN12608000007336Prof Helen Swarbrick75
Recruiting
Not Applicable
Serioss® Bone Study: Testing How Well It Can Fill Empty Spaces in BonesHealth Condition 1: M844- Pathological fracture, not elsewhere classifiedCTRI/2023/10/058843Serigen Mediproducts Pvt Ltd
Active, not recruiting
Phase 1
A controlled, randomised, study investigating the pharmacokineticproperties (to see how active the study drug is in your blood and how long it takes for the study drug to get out of your blood) , surrogate efficacy and safety of Octafibrin compared to Haemocomplettan® P/ RiaSTAPTM in subjects with congenital fibrinogen deficiencyCongenital fibrinogen deficiency (afibrinogenaemia) defined as plasma fibrinogen activity and antigen at screening below detection limit (i.e. <20mg/dl)MedDRA version: 14.1Level: LLTClassification code 10052651Term: AfibrinogenaemiaSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2011-002403-15-DEOCTAPHARMA AG22
Active, not recruiting
Not Applicable
A controlled, randomised, study investigating thepharmacokinetic properties (to see how active the study drug is in your blood and how long it takes for the study drug to get out of your blood) ,surrogate efficacy and safety of Octafibrin compared toHaemocomplettan® P/ RiaSTAPTM in subjects with congenital fibrinogen deficiencyEUCTR2011-002403-15-ITOCTAPHARMA AG18